

In the Specification:

The corrections made to the Specification, excluding the claims, are described below with reference to the as-filed Specification.

At page ~~3~~, line 9, "20 d]." has been rewritten as -20 days]-.

At page ~~4~~, line 33, "particularly" has been rewritten as - particular-.

At page ~~9~~, line 24, "gab" has been rewritten as -gap-.

At page ~~18~~, line 29, "p-nitrophenol" has been rewritten as -p-nitrophenyl-.

At page ~~18~~, line 35, "phosphate" has been deleted.

At page ~~29~~, line 2, "and" has been deleted.

At page ~~32~~, line 8, the generic and ownership information has been added for Polybrene.

At page ~~33~~, lines 19 and 20, trademarked names have been capitalized.

At page ~~33~~, line 27, "immunosupressed" has been rewritten as -immunosuppressed-.

? At page 34, line 35, "MgCl2" has been rewritten as -MgCl₂- and Nonidet has been capitalized.

At page 35, lines 2 and 3, chemical formulae have been corrected to include subscripts, "Nonidet" has been capitalized and the generic description has been inserted.

At page 35, a period has been inserted after "H&E".

~2

At page 36, lines 21 and 24, "RNAzol" has been capitalized

At page 37, line 36, "RNAzol" has been capitalized and the generic information has been incorporated.

At page 42, line 23, "wereharvested" has been rewritten as -were harvested-.

At page 42, line 35, spacing has been corrected.

At page 43, line 21, "RNAzol" has been capitalized.

At page 43, line 25-26, "RNAeasy" has been capitalized.

At page 44, line 15, "p-nitrophenol" has been rewritten as -p-nitophenyl-.

At page 44, lines 33 and 35, "Nonidet" has been capitalized.

At page 45, line 8, the reference to "Sigma" has been amended to recite -Sigma Chemical co., St. Louis, MO-.

At page 45, lines 31 and 32, "vitrogen" has been deleted.

At page 46, line 12, "CholestetR" has been rewritten as -COLLASTAT-.

At page 47, line 30, "Formed" has been rewritten as -formed-.

At page 48, line 30, "onthe" has been rewritten as -on the-.

At page 50, line 9, "humanBMP-2" has been rewritten as -human BMP-2--.

At page 50, line 14, "ofrhBMP-2." has been rewritten as -of rhBMP-2--.

At page 50, line 22, "directedby" has been rewritten as -directed by--.

At page 50, line 32, "ifone" has been rewritten as -if one--.

At page 51, line 20, "overexpresing" has been rewritten as -overexpressing--.

At page 52, line 7, a space has been inserted after ""(2 mM),".

At page 52, line 13, "CholestatR" has been rewritten as -COLLASTAT--.

At page 52, lines 21-22, "De-cal" has been capitalized and generic information has been incorporated.

At page 53, line 33, spacing in "bonemineralized" has been corrected.

In the Claims:

15. (Twice amended) The method of 11 wherein said cell contains an endogenous bone morphogenesis protein receptor.

REMARKS

With the entry of the present amendment, claims 11-12, 14-17 and 19-23 are in this application. Claim 15 has been amended for correct dependency. The Specification has been amended to correct inadvertent typographical and clerical errors and to identify trademarked